ASCERTAIN: an Open-Label, Randomized, Phase 1, Window-of-opportunity Study to Investigate the Biological Effects of AZD5305 and Darolutamide Alone or in Combination in Men with Prostate Cancer Eligible for Radical Prostatectomy.
JOURNAL OF CLINICAL ONCOLOGY（2024）
Key words
283-183-180,613-225-3248-9542-9243,613-4678-146,613-135-2370-7650-11339,2946,2946,162,109,38092-29068,38092-29075,38092-24265
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined